As companies develop commercial space stations and launch experiments in orbit, the most promising markets emerging for microgravity research are in health care.

The lack of gravity creates an environment in which compounds can form unique crystals crucial to drug development in the pharmaceutical industry, but it also unlocks possibilities for human organ development.

In microgravity you have the ability to manufacture and 3D print organs in a way where you can actually use the person's own bio print to and stem cells to develop out the organ and because a lot of

terrestrial printing of a bio printing on earth is affected by gravity.

Microgravity has a lot of potential

for making that process a lot more successful

because we don't have to worry about the organ collapsing on itself

while it's being printed.

Redwire is on the forefront of this capability.

This week, the small cap space company

announced it had successfully 3D bio-printed

the first live human heart tissue sample.

It did this on board the International Space Station, with a sample now undergoing further

testing at its facility in Indiana.

It follows previous work by Red Wire successfully growing

human meniscus and the company says its next biofabrication facility mission

will focus on printing human blood vessels in space. I sat down with Redwire CEO

Peter Canito at last month's space symposium in Colorado Springs prior to the

human heart announcement to discuss the microgravity health care opportunity.

I'm Morgan Brennan and this is Manifest Space.

Joining me now, here at the Bay Symposium, Peter Canito of Red Wire, CEO of Red Wire.

So great to speak with you.

...